Grade 3/4 treatment emergent adverse events (TEAEs) (>1 patient) were keratitis (15%), corneal epithelial microcysts
(8%), hemiparesis (6%), hyperglycemia (6%), muscular weakness (6%), seizure (6%), blurred vision (4%) and ulcerative keratitis (4%).
However, an epithelial defect (see Figure 3), loose epithelium, epithelial microcysts and map lines/ fingerprints can be present in many cases.
A history of previous trauma to the eye, recurrent episodes of pain on waking, family history of RCES and epithelial microcysts make diagnosis straightforward.
with degeneration of basal epithelial cells are associated with the use of cytarabine16.
Ophthalmologic consultation showed bilateral multiple diffuse corneal epithelial microcysts and mild superficial punctate epitheliopathy (Figure 1).
Systemic use at high doses may also produce corneal and conjunctival epithelial toxicity, with conjunctival hyperemia, punctate keratopathy, and corneal epithelial microcysts (4).
Epithelial oedema characterises the third stage and fine epithelial microcysts
are noted with irregular surface texture observed on sclerotic scatter.
In patients with (ABMD) and a history of RCES, the HRT II RCM showed an abnormal epithelial basement membrane protruding forward into the corneal epithelium, the presence of epithelial microcysts and normal superficial epithelial cells and stroma.
In patients with a history of previous trauma to the involved eye, episodes of pain on awakening, and epithelial microcysts, the diagnosis constitutes minimal clinical challenge.